Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies: A Prospective Follow-up Study

por de Vries Lentsch, Simone, van der Arend, Britt W.H., Maassen VanDenBrink, Antoinette, Terwindt, Gisela M.
Publicado 2022

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain

por Lipton, Richard B., Dodick, David W., Goadsby, Peter J., Burstein, Rami, Adams, Aubrey M., Lai, Jeff, Yu, Sung Yun, Finnegan, Michelle, Kuang, Amy W., Trugman, Joel M.
Publicado 2022

Neurofilament Light Chain Levels Are Predictive of Clinical Conversion in Radiologically Isolated Syndrome

por Rival, Manon, Thouvenot, Eric, Du Trieu de Terdonck, Lucile, Laurent-Chabalier, Sabine, Demattei, Christophe, Uygunoglu, Ugur, Castelnovo, Giovanni, Cohen, Mikael, Okuda, Darin T., Kantarci, Orhun H., Pelletier, Daniel, Azevedo, Christina, Marin, Philippe, Lehmann, Sylvain, Siva, Aksel, Mura, Thibault, Lebrun-Frenay, Christine
Publicado 2022

Comparison of Fixed and Live Cell-Based Assay for the Detection of AChR and MuSK Antibodies in Myasthenia Gravis

por Spagni, Gregorio, Gastaldi, Matteo, Businaro, Pietro, Chemkhi, Zeineb, Carrozza, Cinzia, Mascagna, Giovanni, Falso, Silvia, Scaranzin, Silvia, Franciotta, Diego, Evoli, Amelia, Damato, Valentina
Publicado 2022

T065: Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

por Entrop, Joshua P., Weibull, Caroline E., Smedby, Karin E., Jakobsen, Lasse Hjort, øvlisen, Andreas K., Molin, Daniel, Glimelius, Ingrid, Marklund, Anna, Holte, Harald, Fosså, Alexander, Smeland, Knut B., El-Galaly, Tarec Christoffer, Eloranta, Sandra
Publicado 2022

P061: Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma...

por Borchmann, Peter, Johnson, Nathalie A., Lavie, David, Gregory, Gareth, Herrera, Alex F., Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Nahar, Akash, Timmerman, John
Publicado 2022

P089: Pembrolizumab in Pediatric and Young Adults Patients With Newly Diagnosed Classical Hodgkin Lymphoma and Slow Early Responders to Frontline Chemotherapy: The Phase 2 KEYNOTE-...

por Vinti, Luciana, Daw, Stephen, Alvarez, Constantino Sabado, Fagioli, Franca, Beishuizen, Auke, Michel, Gerard, Moleti, Maria Luisa, Cepelova, Michaela, Thorwarth, Anne, Rigaud, Charlotte, De Sabando, Diego Plaza Lopez, Parker, Judith Landman, Zhu, Ying, Pillai, Pallavi, Nahar, Akash, Mauz-Koerholz, Christine
Publicado 2022

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK

por Shakir, Rebecca, Gilmour-Hamilton, Catriona, Bakin, Craig, Gent, Isabelle, Holloway, Adam, Meeson, Alison, Ramroth, Johanna, Ntentas, Georgios, Cutter, David, Peters, Michele
Publicado 2022

P069: Characterisation of influencing parameters on oocyte quality preservation in a cohort of Hodgkin lymphoma patients

por Chuzel, Chloé, Simon, Virginie, Béhal, Hélène, Morschhauser, Franck, Decanter, Christine, Nudel, Morgane
Publicado 2022

P023: PET2-adapted approach after 2 cycles of ABVD is comparable to 2 cycles of BEACOPP escalated and 2 cycles of ABVD and irradiation in early unfavorable Hodgkin lymphoma

por Mocikova, Heidi, Markova, Jana, Gaherova, Lubica, Maco, Maria, Sýkorová, Alice, Belada, David, Lukášová, Marie, Prochazka, Vit, Duras, Juraj, Kozak, Tomas
Publicado 2022

P005: Age, histotype and stage IV are associated with a shorter survival in patients with Hodgkin lymphoma, even the PET-adapted era. A single center retrospective study.

por Visentin, Andrea, Cellini, Alessandro, Cavarretta, Chiara Adele, Gargarella, Leila Romano, Angotzi, Francesco, Ruocco, Valeria, Zoletto, Simone, Pravato, Stefano, Pizzi, Marco, Vianello, Federica, Crimì, Filippo, Vio, Stefania, Gregianin, Michele, Trentin, Livio
Publicado 2022

T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma

por Karihtala, Kristiina, Leivonen, Suvi-Katri, Karjalainen-Lindsberg, Marja-Liisa, Östman, Arne, Pellinen, Teijo, Leppä, Sirpa
Publicado 2022

P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHE...

por Hutchings, Martin, Ansell, Stephen M., Connors, Joseph M., Kim, Won Seog, Gallamini, Andrea, Ramchandren, Radhakrishnan, Friedberg, Jonathan W., Advani, Ranjana, Evens, Andrew M., Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Eom, Hyeon-Seok, Abramson, Jeremy S., Dong, Cassie, Campana, Frank, Fenton, Keenan, Puhlmann, Markus, Straus, David J., Radford, John
Publicado 2022

T084: Treatment patterns and outcomes for Hodgkin’s Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

por Goveia, Lilian, Castro, Nelson, De Souza, Carmino, Villarim, Carolina Colaço., Traina, Fabiola, Chiattone, Carlos Sergio, Praxedes, Monica, Solza, Cristiana, Perobelli, Leila, Baiocchi, Otavio, Gaiolla, Rafael, Boquimpani, Carla, Buccheri, Valeria, Sola, Caroline Bonamin, Silva, Roberta Oliveira De Paula E., Ribas, Ana Carolina, Steffenello, Giovana, Pagnano, Katia, Soares, Andrea, Medina, Samuel Souza, Silveira, Talita, Cecyn, Karin Zattar, Palma, Leonardo Carvalho, De Oliveira Marques, Mariana, Spector, Nelson, Biasoli, Irene
Publicado 2022

P015: Real World Escalated BEACOPDac Delivers Similar Outcomes to Escalated BEACOPP While Potentially Reducing Haematopoietic and Reproductive Toxicity

por Santarsieri, Anna, Sturgess, Katherine, Brice, Pauline, Menne, Tobias F., Osborne, Wendy, Creasey, Thomas, Ardeshna, Kirit M., Behan, Sarah, Bhuller, Kaljit, Booth, Stephen, Chavda, Nikesh, Collins, Graham P., Culligan, Dominic, Cwynarski, Kate, Davies, Andrew, Dutton, David, Furtado, Michelle, Gallop-Evans, Eve, Hodson, Andrew, Hopkins, David, Hsu, Hannah, Iyengar, Sunil, Jones, Stephen G., Linton, Kim, Lomas, Oliver, Martinez-Calle, Nicolas, Mathur, Abhinav, Mckay, Pamela, Nagumantry, Sateesh K., O’Mahony, Deidre, Phillips, Beth, Phillips, Neil, Rudge, John F., Shah, Nimish, Stafford, Gwyneth, Sternberg, Alex, Trickey, Rachel, Uttenthal, Benjamin J., Wetherall, Natasha, Mcmillan, Andrew K., Follows, George A.
Publicado 2022

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience

por Erenmalm, Axel, Linderoth, Johan
Publicado 2022

P040: LINE-1 reverse transcriptase activity in Hodgkin lymphoma cells

por Wadel, Annika, Jaster, Leonie, Staege, Martin S.
Publicado 2022

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.

por Mulder, Tom A., Andersson, Maria L., Peña-Pérez, Lucia, Heimersson, Kia, Xagoraris, Ioanna, Wahlin, Björn E., Månsson, Robert, Hansson, Lotta, Rassidakis, Georgios Z., Palma, Marzia
Publicado 2022

P062: The efficacy and safety of nivolumab 40 mg therapy versus 3 mg/kg in patients with relapsed and refractory classic Hodgkin lymphoma

por Fedorova, Liudmila, Lepik, Kirill, Mikhailova, Natalia, Kondakova, Elena, Komarova, Yaroslava, Kotselyabina, Polina, Borzenkova, Evgenia, Baykov, Vadim, Moiseev, Ivan, Kulagin, Alexander
Publicado 2022

P044: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma

por Szydłowski, Maciej, Garbicz, Filip, Kurtz, Ewa, Pawlak, Michał, Górniak, Patryk, Szumera-Ciećkiewicz, Anna, Sokół., Kamil, Kawecka, Monika, Owczarek, Daria, Puton, Beata, Prochorec-Sobieszek, Monika, Bellarosa, Daniela, Kurlapski, Michał, Zaucha, Jan Maciej, Juszczyński, Przemysław
Publicado 2022